Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nd1-Phosphonohistidine (DrugBank ID: DB01899) is an experimental small molecule and a phosphorylated derivative of the amino acid L-histidine. It is characterized by a phosphate group covalently bonded to the N-delta (pi) nitrogen of the imidazole ring. In biological systems, phosphohistidine isomers function as high-energy intermediates in various phosphotransfer reactions, most notably within bacterial two-component signaling systems and in the catalytic cycles of enzymes such as nucleoside diphosphate kinase and succinyl-CoA synthetase. Due to the acid-lability of the phosphoramidate (P-N) bond, this compound is chemically distinct from the more stable O-phosphorylated amino acids like phosphoserine. Currently, Nd1-phosphonohistidine is classified as an experimental compound with no approved therapeutic indications, no active clinical trials, and no identified commercial developers or brand names.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nd1-phosphonohistidine.